Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension of Higher-Dose Nusinersen (Spinraza) in SMA Participants from Study 203
jRCT2031260173Active, not recruiting
- Sponsor
- Biogen
- Start
- Aug 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Open-label trial of nusinersen in spinal muscular atrophy (SMA) (2 arms), sponsored by Biogen. Primary endpoints: Incidence of adverse events, Change in growth parameters and 6 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on jRCT2031260173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260173.